Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
Trump Administration Joins Challenge to CO’s AI Law On April 24, the U.S. Department of Justice joined a lawsuit brought by Elon Musk’s AI company, xAI, seeking to block Colorado’s...
Trump Administration Expands Medicaid Fraud Scrutiny to All 50 States In an effort to fight fraud, the Centers for Medicare and Medicaid Services is requiring all 50 states to submit plans for revalidating...
On Jan. 7, 2025, two weeks before Donald Trump was inaugurated, the Consumer Financial Protection Bureau under the Biden administration issued a new rule barring credit reporting agencies from reporting...
ME Lawmakers Pass Data Center Ban The Maine Legislature passed a bill ( HB 207 ) that would make the state the first to temporarily ban the development of large data centers. The measure would impose...
State and Federal Funding Flowing for Ibogaine Research President Donald Trump signed an executive order providing up to $50 million in federal funding for states to conduct research on ibogaine, a psychedelic...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
With popular weight-loss drugs like Mounjaro, Ozempic and Wegovy in short supply, many doctors, pharmacies and other providers have begun offering compounded versions of the drugs tailored to the needs of individual patients. They’re allowed to do so because the active ingredients in the drugs—semaglutide or tirzepatide—are listed on the U.S. Food and Drug Administration’s drug shortage list.
While commercial drugs are regulated by the FDA, states are responsible for the licensing and oversight of compounding pharmacies, and they’re now struggling to stay on top of that job. Idaho and Tennessee recently announced investigations of medical spas and other providers that may have been dispensing compounded weight-loss drugs illegally. And California and other states are considering strengthening their oversight of providers that offer such drugs. (NATIONAL CONFERENCE OF STATE LEGISLATURES)
Vermont Attorney General Charity Clark (D) filed a lawsuit against pharmacy benefit managers Express Scripts and CVS Caremark, accusing them of squeezing out competition and driving up prescription drug costs. The suit claims the two PBMs control more than 95% of Vermont’s pharmacy benefit market, giving them the power to dictate which drugs are covered by insurers. (LAW360)
AstraZeneca and AbbVie have filed lawsuits challenging legislation enacted in Kansas in April (SB 28) preventing drug companies from limiting the ability of pharmacies under contract with eligible hospitals and clinics to obtain outpatient prescription drugs at discounted prices, as provided for by the federal 340B drug discount program. The drug makers claim the federal program wasn’t intended to cover pharmacy chains like CVS and Walgreens. (KANSAS REFLECTOR)
—Compiled by SNCJ Managing Editor KOREY CLARK
Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.